CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 66 enrolled
Drug / intervention
LY3074828 +2 moredrug
Likely dose
Not stated in record
Key inclusion· 1
  • ✓Must be healthy males or females
Key exclusion· 10
  • ✕Active or latent tuberculosis
  • ✕Live vaccine(s) within 8 weeks of screening or planned during study
  • ✕Systemic steroid treatment within 1 month of screening or planned during study
  • ✕Immunocompromised status

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03886948
NCT03886948Phase 1Completed
CompareCT.gov

A Safety, Tolerability, and Pharmacokinetic Study of Injections of LY3074828 Solution Using Investigational 1-mL Pre-filled Syringes and Investigational 1-mL Autoinjector in Healthy Subjects

Eli Lilly and Company·interventional·Posted Mar 22, 2019·Updated Feb 20, 2024

In Brief

A Phase 1 clinical trial evaluating LY3074828, Pre-filled syringe (PFS), and 1 other intervention for Healthy. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The purpose of this study is to learn about the effects of LY3074828 when given as an injection just under the skin by two different devices. The study will last about 12 weeks for each participant.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedMar 22, 2019
Enrollment StartMar 27, 2019
Primary CompletionOct 4, 2019
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 7.3 years ago

Interventions

LY3074828drug

Administered subcutaneously (SC)

Pre-filled syringe (PFS)device

PFS used to administer LY3074828

Autoinjector (AI)device

AI used to administer LY3074828